2-Amino-6-dimethyl-amino-purin | 5437-49-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-Amino-6-dimethyl-amino-purin
• 英文别名: 2-amino-6-N,N-dimethylamino-purine；2-amino-6-dimethylamino purine；N⁶,N⁶-dimethyl-7(9)H-purine-2,6-diamine；N⁶,N⁶-dimethyl-7(9)H-purine-2,6-diyldiamine；N⁶,N⁶-Dimethyl-7(9)H-purin-2,6-diyldiamin；N6,N6-Dimethyl-9H-purine-2,6-diamine；6-N,6-N-dimethyl-7H-purine-2,6-diamine
• CAS: 5437-49-0
• 化学式: C₇H₁₀N₆
• 分子量: 178.197
• InChiKey: GHILAORILZRWPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  83.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-Amino-6-dimethyl-amino-purin 在 pyridinium hydrobromide perbromide 作用下， 以 二氯甲烷 为溶剂， 反应 55.0h， 以46%的产率得到2-amino-8-bromo-6-dimethylaminopurine
  参考文献：
  名称：

  8-Bromination of 2,6,9-trisubstituted purines with pyridinium tribromide

  摘要：

  2,6,9-Trisubstituted purines are brominated in high yields using pyridinium tribromide as the brominating reagent. This procedure works excellently for electron-rich purines having electron-donating substituents at the 2- and 6-positions. The use of pyridinium tribromide, a crystalline alternative to elemental bromine, improves the bromination procedure for this type of substrate as the reagent is easy to handle and the work-up and purification procedures are simplified. (C) 2014 The Authors. Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2014.03.084
• 作为产物：
  描述：

  2-氨基-6-氯嘌呤 以 水 、 二甲胺 为溶剂， 生成 2-Amino-6-dimethyl-amino-purin
  参考文献：
  名称：

  3'-Azido nucleoside compound

  摘要：

  本发明涉及3'-氮杂基嘌呤核苷及其在医学治疗中的应用，特别是用于治疗人类免疫缺陷病毒和乙型肝炎病毒感染，以及其制备方法和含有它们的组合物。

  公开号：

  US05153318A1
• 作为试剂：
  描述：

  2-羟基丙烷-1,2,3-三羧酸根 、 2-Amino-6-dimethyl-amino-purin 、 齐多夫定 在 solution 、 2-Amino-6-dimethyl-amino-purin 、 乙酸乙酯 、 magnesium sulfate 、 silica gel 、 chloroform methanol 作用下， 反应 504.0h， 以to give the product as a solid (41% yield)的产率得到2-amino-9-(3-azido-2,3-dideoxy-β-D-erythro-pentofuranosyl)-6-dimethylamino-9H-purine
  参考文献：
  名称：

  3'-Azido nucleoside compound

  摘要：

  本发明涉及3'-azido嘌呤核苷及其在医学治疗中的应用，特别是用于治疗人类免疫缺陷病毒和乙型肝炎病毒感染的方法，以及它们的制备方法和含有它们的组合物。

  公开号：

  US05153318A1

文献信息

• Synthesis and Cytostatic Activity of N-[2-(Phosphonomethoxy)alkyl] Derivatives of N6-Substituted Adenines, 2,6-Diaminopurines and Related Compounds
  作者：Antonín Holý、Ivan Votruba、Eva Tloušťová、Milena Masojídková

  DOI：10.1135/cccc20011545

  日期：——

  N⁶-Substituted adenine and 2,6-diaminopurine derivatives of 9-[2-(phosphonomethoxy)- ethyl] (PME), 9-[(R)-2-(phosphonomethoxy)propyl] [(R)-PMP] and enantiomeric (S)-PMP series were synthesized by reactions of primary or secondary amines with 6-chloro-9-[2-(diisopropoxyphosphoryl)methoxy]alkyl}purines (26-28) or 2-amino-6-chloro-9-[2-(diisopropoxy- phosphoryl)methoxy]alkyl}purines (29-31) followed by treatment of the diester intermediates32with bromo(trimethyl)silane and hydrolysis. Diesters32were also obtained by reaction ofN⁶-substituted purines with synthons23-25bearing diisopropoxyphosphoryl group. Alkylation of 2-amino-6-chloropurine (9) with diethyl [2-(2-chloroethoxy)ethyl]phosphonate (148) gave the diester149which was analogously converted toN⁶-substituted 2,6-diamino- 9-[2-(2-phosphonoethoxy)ethyl]purines151-153. Alkylation ofN⁶-substituted 2,6-diaminopurines with (R)-[(trityloxy)methyl]oxirane (155) followed by reaction of thus-obtained intermediates156with dimethylformamide dimethylacetal and condensation with diisopropyl [(tosyloxy)methyl]phosphonate (158) followed by deprotection of the intermediates159gaveN⁶-substituted 2,6-diamino-9-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]purines160-163. The highest cytostatic activityin vitrowas exhibited by the followingN⁶-derivatives of 2,6-diamino-9-[2-(phosphonomethoxy)ethyl]purine (PMEDAP): 2,2,2-trifluoroethyl (53), allyl (54), [(2-dimethylamino)ethyl] (68), cyclopropyl (75) and dimethyl (91). In CCRF-CEM cells, the cyclopropyl derivative75is deaminated to the guanine derivative PMEG (3) which is then converted to its diphosphate.

  N6-取代腺嘌呤和2,6-二氨基嘌呤衍生物9-[2-(磷酸甲氧基)-乙基]（PME）、9-[(R)-2-(磷酸甲氧基)丙基] [(R)-PMP] 和对映体(S)-PMP 系列通过初级或次级胺与6-氯-9-[2-(二异丙氧磷酰基)甲氧基]烷基}嘌呤（26-28）或2-氨基-6-氯-9-[2-(二异丙氧磷酰基)甲氧基]烷基}嘌呤（29-31）的反应合成，随后用溴化(三甲基)硅烷和水解处理二酯中间体32。二酯32也可通过N6-取代嘌呤与带有二异丙氧磷酰基的合成物23-25发生反应获得。2-氨基-6-氯嘌呤（9）与二乙基[2-(2-氯乙氧基)乙基]磷酸酯（148）的烷基化反应得到二酯149，类似地转化为N6-取代2,6-二氨基-9-[2-(2-磷酸乙氧基)乙基]嘌呤151-153。N6-取代2,6-二氨基嘌呤与(R)-[(三苄氧基)甲基]环氧乙烷（155）发生烷基化反应，随后用二甲基甲酰胺二甲基缩醛和与异丙基[(对甲苯磺酰氧基)甲基]磷酸酯（158）发生缩合反应，然后去保护中间体159得到N6-取代2,6-二氨基-9-[(S)-3-羟基-2-(磷酸甲氧基)丙基]嘌呤160-163。体外细胞毒活性最高的是以下2,6-二氨基-9-[2-(磷酸甲氧基)乙基]嘌呤（PMEDAP）的N6-衍生物：2,2,2-三氟乙基（53）、烯丙基（54）、[(2-二甲基氨基)乙基]（68）、环丙基（75）和二甲基（91）。在CCRF-CEM细胞中，环丙基衍生物75被脱氨基化为鸟嘌呤衍生物PMEG（3），然后转化为其二磷酸盐。
• [EN] BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION<br/>[FR] NUCLÉOTIDES DE PURINE BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUÉ-4'-FLUORO-N6-SUBSTITUÉ-6-AMINO-2-SUBSTITUÉ POUR LE TRAITEMENT DE L'INFECTION PAR LE VIRUS DE L'HÉPATITE C
  申请人：ATEA PHARMACEUTICALS INC

  公开号：WO2018013937A1

  公开（公告）日：2018-01-18

  Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX and Formula X that are highly active against the HCV virus when administered in an effective amount to a host in need thereof. The host can be a human or any animal that carries the viral infection. Methods of treating a subject suffering from a condition related to viral infections are also provided.

  当以有效剂量给予宿主时，化合物I、化合物II、化合物III、化合物IV、化合物V、化合物VI、化合物VII、化合物VIII、化合物IX和化合物X对HCV病毒具有高活性。宿主可以是患有病毒感染的人类或任何动物。还提供了治疗与病毒感染相关疾病的方法。
• General method for nucleophilic aromatic substitution of aryl fluorides and chlorides with dimethylamine using hydroxide-assisted decomposition of N,N-dimethylforamide
  作者：Juana Garcia、Jacob Sorrentino、Emily J. Diller、Daniel Chapman、Zachary R. Woydziak

  DOI：10.1080/00397911.2016.1147051

  日期：2016.3.3

  and convenient procedure for the nucleophilic aromatic substitution of aryl fluorides and chlorides with dimethylamine was developed using a hydroxide-assisted thermal decomposition of N,N-dimethylforamide. These conditions are tolerant of nitro, nitrile, aldehyde, ketone, and amide groups but will undergo acyl substitution to form amides for methyl esters and acyl chlorides. Isolated yields of the products

  摘要 利用 N,N-二甲基甲酰胺的氢氧化物辅助热分解，开发了一种实用且方便的方法，用于芳基氟化物和氯化物与二甲胺的亲核芳香取代。这些条件耐受硝基、腈、醛、酮和酰胺基团，但会发生酰基取代以形成甲酯和酰氯的酰胺。产品的分离产率范围为 44% 至 98%，其中 17 个实例的大多数产率大于 70%。图形概要
• 2',3'-dideoxy-3'-fluoro-purine ribonucleosides
  申请人：Glaxo Wellcome Inc.

  公开号：US05663154A1

  公开（公告）日：1997-09-02

  2',3'-Dideoxy-3'-fluoro-(B-D-ribofuranosyl) purine nucleosides possessing the ability to inhibit hepatitis B and HIV viral infections.

  2',3'-二脱氧-3'-氟-(B-D-核糖呋喃基) 嘌呤核苷具有抑制乙型肝炎和HIV病毒感染的能力。
• Dynamic Kinetic Resolution of α-Purine Substituted Alkanoic Acids: Access to Chiral Acyclic Purine Nucleosides
  作者：Huifang Zhang、Mingsheng Xie、Guirong Qu、Junbiao Chang

  DOI：10.1021/acs.orglett.8b03555

  日期：2019.1.4

  An efficient route to construct chiral acyclic purine nucleoside analogues via dynamic kinetic resolution of α-purine substituted alkanoic acids is reported. Using (S)-BTM as the catalyst, diverse chiral acyclic purine nucleoside analogues were obtained in moderate to good yields (up to 93%) and high enantioselectivities (up to 98% ee). Chiral acyclic purine nucleosides could be obtained from the esterified

  报道了通过α-嘌呤取代的链烷酸的动态动力学拆分来构建手性无环嘌呤核苷类似物的有效途径。使用（S）-BTM作为催化剂，可以以中等至良好的收率（高达93％）和高的对映选择性（高达98％ee）获得各种手性无环嘌呤核苷类似物。可以通过还原反应从酯化产物中获得手性无环嘌呤核苷，然后将其转移到替诺福韦类似物中。